Progress in Clinical Neurosciences: A Forum on the Early Management of Parkinson's Disease

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques

• Publication date

  2005-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1017/S0317167100004145PMID 16225167
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP‐treated drug‐naïve primates

  2005cited by this paper
• Pramipexole v. Levodopa as Initial Treatment for Parkinson’s Disease: A Randomized Clinical-Economic Trial

  2004cited by this paper
• Disabling repetitive behaviors in Parkinson's disease

  2004cited by this paper
• Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.

  2004cited by this paper
• Quality of life in early Parkinson's disease: Impact of dyskinesias and motor fluctuations

  2004cited by this paper
• Neuroprotective agents for clinical trials in Parkinson’s disease: A systematic assessment

  2004cited by this paper
• COMT inhibitors in Parkinson’s disease

  2004cited by this paper
• Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease.

  2004cited by this paper
• Repetition, repetition, and repetition: Compulsive and punding behaviors in parkinson's disease

  2004cited by this paper
• Punding in Parkinson's disease: Its relation to the dopamine dysregulation syndrome

  2004cited by this paper
• Gait assessment in Parkinson's disease: toward an ambulatory system for long-term monitoring

  2004cited by this paper
• Levodopa and the progression of Parkinson's disease.

  2004cited by this paper
• Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.

  2004cited by this paper
• Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists

  2004cited by this paper
• Surgery for Parkinson's disease, the five W's: why, who, what, where, and when.

  2003cited by this paper
• Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of L-DOPA and pramipexole.

  2003cited by this paper
• Slowing Parkinson’s disease progression

  2003cited by this paper
• Looking Backward to Move Forward: Early Detection of Neurodegenerative Disorders

  2003cited by this paper
• A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease

  2003cited by this paper
• Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson’s disease: a randomised, placebo controlled, double blind, six month study

  2003cited by this paper
• Initial agonist treatment of Parkinson disease

  2003cited by this paper
• Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease.

  2003cited by this paper
• Tremor in Parkinson’s disease and serotonergic dysfunction

  2003cited by this paper
• Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study

  2003cited by this paper
• Levodopa Is Toxic to Dopamine Neurons in an in Vitro but Not an in Vivo Model of Oxidative Stress

  2003cited by this paper
• The placebo effect in Parkinson's disease.

  2002cited by this paper
• Practice parameter: Initiation of treatment for Parkinson’s disease: An evidence-based review

  2002cited by this paper
• Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.

  2002cited by this paper
• Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal Levodopa response: a 6‐month randomized placebo‐controlled double‐blind study in Germany and Austria (Celomen study)

  2002cited by this paper
• Parkinson’s disease and sleepiness: An integral part of PD

  2002cited by this paper
• SCA-2 presenting as parkinsonism in an Alberta family

  2002cited by this paper
• 18F‐dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease

  2002cited by this paper
• Influence of l-dopa and pramipexole on striatal dopamine transporter in early PD

  2001cited by this paper
• Transplantation of embryonic dopamine neurons for severe Parkinson's disease.

  2001cited by this paper
• Pathologic gambling in patients with Parkinson's disease.

  2001cited by this paper
• Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature

  2001cited by this paper
• Sudden daytime sleep onset in Parkinson's disease: Polysomnographic recordings

  2001cited by this paper
• Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model.

  2000cited by this paper
• Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

  2000cited by this paper
• Waking up to sleep episodes in Parkinson's Disease

  2000cited by this paper
• A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.

  2000cited by this paper
• Preventing levodopa-induced dyskinesias.

  2000cited by this paper
• Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications.

  2000cited by this paper
• In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease

  2000cited by this paper
• Immediate-release and controlled-release carbidopa/levodopa in PD

  1999cited by this paper
• The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease

  1999cited by this paper
• The role of inheritance in sporadic Parkinson's disease: Evidence from a longitudinal study of dopaminergic function in twins

  1999cited by this paper
• Punding on L‐dopa

  1999cited by this paper
• Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole

  1999cited by this paper
• Long‐term intraduodenal infusion of a water based levodopa‐carbidopa dispersion in very advanced Parkinson's disease

  1998cited by this paper
• Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease

  1998cited by this paper
• Parkinson's disease. First of two parts.

  1998cited by this paper
• Early Treatment of Parkinson’s Disease with Cabergoline Delays the Onset of Motor Complications

  1998cited by this paper
• De novo administration of ropinirole and bromocriptine induces less dyskinesia than L‐dopa in the MPTP‐treated marmoset

  1998cited by this paper
• Trauma exposure, postmigration stressors, and symptoms of anxiety, depression and post‐traumatic stress in Tamil asylum‐seekers: comparison with refugees and immigrants

  1998cited by this paper
• Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?

  1997cited by this paper
• Timely levodopa (LD) administration prolongs survival in Parkinson's disease.

  1997cited by this paper
• Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease

  1997cited by this paper
• [11C]RTI‐32 PET studies of the dopamine transporter in early dopa‐naive Parkinson's disease

  1997cited by this paper
• Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease.

  1997cited by this paper
• In vivo radiotracers for vesicular neurotransmitter transporters.

  1997cited by this paper
• Prevalence of parkinsonian signs and associated mortality in a community population of older people.

  1996cited by this paper
• Sustained‐release Madopar HBS® compared with standard Madopar® in the long‐term treatment of de novo parkinsonian patients

  1996cited by this paper
• Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations.

  1996cited by this paper
• The Vesicular Monoamine Transporter, in Contrast to the Dopamine Transporter, Is Not Altered by Chronic Cocaine Self-Administration in the Rat

  1996cited by this paper
• [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease.

  1996cited by this paper
• Scavenging Effects of Dopamine Agonists on Nitric Oxide Radicals

  1996cited by this paper
• Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa

  1996cited by this paper
• [sup 123 I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease

  1996cited by this paper
• Isolated involvement of substantia nigra in acute transient parkinsonism: MRI and PET observations.

  1995cited by this paper
• A new PET ligand for the dopamine transporter: studies in the human brain.

  1995cited by this paper
• Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys.

  1995cited by this paper
• The vesicular monoamine transporter is not regulated by dopaminergic drug treatments.

  1995cited by this paper
• Early differential diagnosis of Parkinson's disease with 18F‐fluorodeoxyglucose and positron emission tomography

  1995cited by this paper
• Behavior-related activity of primate dopamine neurons.

  1994cited by this paper
• Effect of peripheral catechol‐O‐methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients

  1994cited by this paper
• Clinical aspects of motor fluctuations in Parkinson's disease.

  1994cited by this paper
• Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration.

  1994cited by this paper
• Human positron emission tomographic [18F]Fluorodopa studies correlate with dopamine cell counts and levels

  1993cited by this paper
• Correlation of striatal fluorodopa uptake in the MPTP Monkey with dopaminergic indices

  1993cited by this paper
• Positron emission tomographic imaging of the dopamine transporter with 11C‐WIN 35,428 reveals marked declines in mild Parkinson's disease

  1993cited by this paper
• Double‐blind, placebo‐controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on‐off' fluctuations

  1993cited by this paper
• Levodopa therapy and survival in idiopathic Parkinson's disease

  1993cited by this paper
• Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease.

  1993cited by this paper
• The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic

  1992cited by this paper
• The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa

  1991cited by this paper
• “Early” initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease

  1991cited by this paper
• Differing patterns of striatal 18F‐dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy

  1990cited by this paper
• Levodopa therapy in Parkinson's disease

  1990cited by this paper
• Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia.

  1990cited by this paper
• Effect of deprenyl on the progression of disability in early Parkinson's disease.

  1989cited by this paper
• Jejunal delivery of levodopa methyl ester.

  1989cited by this paper
• Continuous and intermittent levodopa differentially affect basal ganglia function

  1989cited by this paper
• DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group.

  1989cited by this paper
• Long‐term duodenal infusion of levodopa for motor fluctuations in parkinsonism

  1988cited by this paper
• Progression of Parkinson's disease without levodopa

  1987cited by this paper
• Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding.

  1986cited by this paper
• Duodenal delivery of levodopa for on‐off fluctuations in parkinsonism: Preliminary observations

  1986cited by this paper
• Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease

  1985cited by this paper
• The control of firing pattern in nigral dopamine neurons: single spike firing

  1984cited by this paper

• Neurodegenerative disease mechanisms induced by tau fragmentation in a novel model of human tauopathy

  2018cites this paper
• Matrix Metalloproteinase Expression in Models of Parkinson's Disease

  2009cites this paper
• neurological disorders : a public health approach Alcohol-related polyneuropathy

  2007cites this paper
• Identification of novel proteins affected by rotenone in mitochondria of dopaminergic cells

  2007cites this paper
• [The current approaches to diagnostics and therapy of fluctuations in Parkinson's disease].

  2006cites this paper
• Laser Literature Watch

  2006cites this paper
• Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism.

  2006cites this paper
• Delivery of neurturin by AAV2 (CERE‐120)‐mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP‐treated monkeys

  2006cites this paper
• Laser literature watch.

  2006cites this paper